Clinical trials
Macular Degeneration clinical trials
Below are recruiting macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 170 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06662162Recruiting
Microcurrent therapy for dry age-related macular degeneration
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
Poway, CaliforniaAges 60 years+ - NCT07440225RecruitingPhase 2/Phase 3
Testing a new drug for wet macular degeneration
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Scottsdale, ArizonaAges 50 years+ - NCT07496567RecruitingPhase 2/Phase 3
Study of EYE201 for wet age-related macular degeneration
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
Gilbert, ArizonaAges 50 years+ - NCT07367282RecruitingPhase 4
Faricimab for newly diagnosed wet age-related macular degeneration
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
SeongnamAges 50 years+ - NCT04663750RecruitingPhase 3
Surgery to treat bleeding under the retina in wet macular degeneration
This trial tests whether a specific eye surgery plus targeted clot-busting medicine and gas can improve vision after bleeding under the retina from “wet” age-related macular degeneration. It aims to reduce how long the bleeding lasts and help protect the central vision.
BonnAges 50–120 - NCT04739319Recruiting
Study of age-related macular degeneration changes
This study looks closely at how age-related macular degeneration (AMD) develops and changes over time by taking detailed eye measurements. It may help researchers better understand disease progression, especially for people who already have AMD.
East Melbourne, VictoriaAges 18 years+ - NCT04762368Recruiting
Learning study to improve vision support for macular degeneration
This study focuses on adults with macular degeneration and aims to improve how well you can use your remaining vision. It uses learning and brain stimulation, so it may help you notice and use your vision more effectively.
Waterloo, OntarioAges 18 years+ - NCT04847635Recruiting
Laser test for aging-related macular spots under the retina
This trial studies a mild (“subthreshold”) laser treatment for reticular pseudodrusen (RPD) caused by age-related macular degeneration (AMD). If you qualify, the goal is to see whether the laser helps preserve or improve vision by targeting these specific eye changes.
GenovaAges 55 years+ - NCT05445063RecruitingPhase 1
iPSC eye-cell transplant for late dry macular degeneration
This Phase 1 study tests an experimental transplant made from your own cells to try to improve vision in people with advanced “late dry” age-related macular degeneration (AMD). It focuses first on safety, and may help some participants with limited central vision.
Beijing, Beijing MunicipalityAges 50–75 - NCT06394232RecruitingPhase 1/Phase 2
Testing a cell therapy for advanced dry AMD with geographic atrophy
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
Jālna, MaharashtraAges 50–100 - NCT06742307RecruitingPhase 4
Faricimab quarterly shots for wet age-related macular degeneration
This trial tests if faricimab eye injections given every 3 months can keep wet age-related macular degeneration under control. It is for people with a new or returning active blood vessel growth in the center of the macula.
Hong KongAges 50 years+ - NCT07235527Recruiting
Aflibercept biosimilar for wet age-related macular degeneration
This study tests a biosimilar version of aflibercept (a drug that blocks abnormal blood vessel growth) in people with wet age-related macular degeneration. It aims to see how well the treatment works in real life.
Istanbul, şişliAges 45–90 - NCT07434713Recruiting
Testing early response to Eylea 8mg for wet AMD
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
BernAges 50 years+ - NCT03999801Enrolling by invitationPhase 2
Long-term follow-up for a subretinal eye treatment
This study checks how well a previous eye treatment (RGX-314) lasts over time. There is also an extra “other eye” study for people with age-related macular degeneration affecting both eyes.
Phoenix, ArizonaAges 50 years+ - NCT06694272Recruiting
Visual function tests for early age-related macular degeneration
This study looks at how well the eyes function in people with early or intermediate age-related macular degeneration (AMD). It uses imaging and vision tests to help doctors better understand the condition.
ParisAges 18 years+ - NCT06305416RecruitingPhase 3
Ranibizumab for diabetic macular edema
This trial tests an injection called Ranibizumab (10 mg/ml) to treat diabetic macular edema, a condition where fluid builds up in the center of the retina and causes blurry vision. The goal is to see if the drug is safe and effective at improving vision.
DhakaAges 18 years+ - NCT07069647Recruiting
AI screening for diabetic eye disease and macular degeneration
This trial tests if an AI tool can help detect diabetic retinopathy and age-related macular degeneration in older adults visiting family medicine or geriatric clinics. It aims to catch these eye conditions early, before they cause vision loss.
TaipeiAges 20 years+ - NCT06237127Recruiting
Goji berries vs. fiber for age-related macular degeneration
This study compares the effects of eating goji berries versus taking fiber wafers on age-related macular degeneration (AMD). It looks at whether goji berries or fiber can help slow down the eye condition, especially for people with a family history of AMD.
Sacramento, CaliforniaAges 65–95 - NCT03178149RecruitingPhase 1
Study of a new eye treatment for dry macular degeneration
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
Phoenix, ArizonaAges 50 years+ - NCT05454124Recruiting
Study of brain-eye learning changes in macular degeneration
This study looks at how the eye’s “central vision” area and connected brain learning/adjustment work in people with advanced macular degeneration. You may be asked to do vision testing using special eye-scanning equipment and follow study procedures that could help researchers better understand the disease.
Birmingham, AlabamaAges 18–89 - NCT06046118Recruiting
Light therapy for dry age-related macular degeneration
This trial tests whether a special light treatment (photobiomodulation) can help people with dry age-related macular degeneration (AMD). It is designed for those with early to moderate dry AMD who still have fairly good vision.
ParisAges 50 years+ - NCT06635148RecruitingPhase 2
Long-term study for geographic atrophy treatment
This study is for people who already took part in a previous trial for geographic atrophy (a late stage of dry age-related macular degeneration) and received the study drug or a sham. It looks at the long-term safety of the treatment over time.
Tucson, ArizonaAges 60 years+ - NCT06899360Recruiting
Age-related macular degeneration progression study
This study tracks how age-related macular degeneration (AMD) progresses over time and looks at factors that might affect your vision and quality of life. By participating, you'll help researchers understand more about AMD and what might predict better or worse outcomes.
Udine, UDAges 50–120 - NCT07064759RecruitingPhase 3
Gene therapy injection for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
Scottsdale, ArizonaAges 50 years+
Hear when a new Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Macular Degeneration trials by city
Studies with a site in or near these metro areas.
Macular Degeneration trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for macular degeneration?
- Yes. Clin2 currently lists 170 recruiting macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.